Investment Thesis
Picard Medical exhibits severe operational distress with negative gross margins (-4.1%), catastrophic losses ($27M net loss on $4.9M revenue), and unsustainable cash burn ($15.7M annually). With only $7.5M cash and a current ratio of 1.11x, the company faces critical liquidity pressure within 6-12 months absent significant operational improvement or capital infusion. The negative gross margin indicates fundamental business model dysfunction rather than temporary startup scaling challenges.
Strengths
- Revenue growth of 12.5% YoY demonstrates market demand for product
- Cash position of $7.5M provides short-term runway for turnaround efforts
- Zero long-term debt eliminates financial leverage burden
Risks
- Negative gross margin of -4.1% reveals fundamental cost structure or pricing dysfunction
- Annual cash burn of $15.7M against $7.5M cash creates existential solvency risk within 6 months
- Net margin of -546.6% and operating margin of -268.4% indicate company is unsustainable in current form
- Quick ratio of 0.72x below 1.0 threshold signals potential inability to meet short-term obligations
- Zero insider Form 4 filings in 90 days suggests management lacks confidence in near-term recovery
Key Metrics to Watch
- Gross margin trajectory (critical inflection point for viability)
- Monthly cash burn rate and runway remaining
- Revenue growth sustainability and customer retention rates
Financial Metrics
Revenue
4.9M
Net Income
-27.0M
EPS (Diluted)
$0.00
Free Cash Flow
-15.7M
Total Assets
22.5M
Cash
7.5M
Profitability Ratios
Gross Margin
-4.1%
Operating Margin
-268.4%
Net Margin
-546.6%
ROE
-712.6%
ROA
-119.8%
FCF Margin
-317.3%
Balance Sheet & Liquidity
Current Ratio
1.11x
Quick Ratio
0.72x
Debt/Equity
0.00x
Debt/Assets
83.2%
Interest Coverage
-4.45x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T10:45:23.017328 |
Data as of: 2025-12-31 |
Powered by Claude AI